Deuterated clopidogrel analogues as a new generation of antiplatelet agents

ACS Medicinal Chemistry Letters

Volumn 4, Issue 3, 2013, Pages 349-352

  Zhu, Yaoqiu ^a   Zhou, Jiang ^b   Jiao, Bo ^c  

^a MetabQuest Research Laboratory   (China)

^b PEKING UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

bioactivation potentiation; clinical variability; Clopidogrel resistance; piperidine deuteration; prodrug attrition; targeted metabolic shift

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARYLDIALKYLPHOSPHATASE 1; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; DRUG DERIVATIVE; PIPERIDINE DERIVATIVE; PRASUGREL; TICAGRELOR;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR RISK; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TRANSFORMATION; GENOTYPE; HEREDITY; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATIENT COMPLIANCE; POLYMERIZATION; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE;

EID: 84875207365     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300460t     Document Type: Article

References (22)

1. Savi, P.; Herbert, J. M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate receptor antagonists for the prevention of atherothrombosis Semin. Thromb. Hemostasis 2005, 31, 174-183 (Pubitemid 40605192)
2. Pereillo, J. M.; Maftouh, M.; Andrieu, A.; Uzabiaga, M. F.; Fedeli, O.; Savi, P.; Pascal, M.; Herbert, J. M.; Maffrand, J. P.; Picard, C. Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab. Dispos. 2002, 30, 1288-1295 (Pubitemid 35265838)
3. Dansette, P. M.; Libraire, J.; Bertho, G.; Mansuy, D. Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel Chem. Res. Toxicol. 2009, 22, 369-373
4. Gurbel, P. A.; Bliden, K.P.; Hiatt, B. L.; O'Connor, C. M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 2003, 107, 2908-2913 (Pubitemid 36736631)
5. Kolandaivelu, K.; Bhatt, D. L. Overcoming resistance to antiplatelet therapy: targeting the issue of nonadherence Nat. Rev. Cardiol. 2010, 7, 461-467
6. Dansette, P. M.; Rosi, J.; Bertho, G.; Mansuy, D. Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer Chem. Res. Toxicol. 2012, 25, 348-356
7. Gong, I. Y.; Crown, N.; Suen, C. M.; Schwarz, U. I.; Dresser, G. K.; Knauer, M. J.; Sugiyama, D.; Degorter, M. K.; Woolsey, S.; Tirona, R. G.; Kim, R. B. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response Eur. Heart. J. 2012, 33, 2856-2864
8. Zhu, Y.; Zhou, J. Identification of the significant involvement and mechanistic role of CYP3A4/5 in clopidogrel bioactivation ACS Med. Chem. Lett. 2012, 3, 844-849
9. Kazui, M.; Nishiya, Y.; Ishizuka, T.; Hagihara, K.; Farid, N. A.; Okazaki, O.; Ikeda, T.; Kurihara, A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab. Dispos. 2010, 38, 92-99
10. Hagihara, K.; Kazui, M.; Kurihara, A.; Yoshiike, M.; Honda, K.; Okazaki, O.; Farid, N. A.; Ikeda, T. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet gents, prasugrel and clopidogrel Drug Metab. Dispos. 2009, 37, 2145-2152
11. Caplain, H.; Donat, F.; Gaud, C.; Necciari, J. Pharmacokinetics of clopidogrel Semin. Thromb. Hemostasis 1999, 25 (Suppl 2) 25-28 (Pubitemid 29350288)
12. Zhu, Y.; Zhou, J. In Vitro Biotransformation Studies of 2-Oxo-clopidogrel: Multiple Thiolactone Ring Opening Pathways Further Attenuate Prodrug Activation Chem. Res. Toxicol. 2013, 26, 179-190
13. Savi, P.; Pereillo, J. M.; Uzabiaga, M. F.; Combalbert, J.; Picard, C.; Maffrand, J. P.; Pascal, M.; Herbert, J. M. Identification and biological activity of the active metabolite of clopidogrel Thromb. Haemostasis 2000, 84, 891-896
14. Sibbing, D.; Steinhubl, S. R.; Schulz, S.; Schömig, A.; Kastrati, A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window J. Am. Coll. Cardiol. 2010, 56, 317-318
15. Bhatt, D. L.; Fox, K. A. A.; Hacke, W.; Berger, P. B.; Black, H. R.; Boden, W. E.; Cacoub, P.; Cohen, E. A.; Creager, M. A.; Easton, J. D.; Flather, M. D.; Haffner, S. M.; Hamm, C. W.; Hankey, G. J.; Johnston, S. C.; Mak, K.; Mas, J.; Montalescot, G.; Pearson, T. A.; Steg, P. G.; Steinhubl, S. R.; Weber, M. A.; Brennan, D. M.; Fabry-Ribaudo, L.; Booth, J.; Topol, E. J. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N. Engl. J. Med. 2006, 354, 1706-1717
16. Zhang, H.; Amunugama, H.; Ney, S.; Cooper, N.; Hollenberg, P. F. Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme Mol. Pharmacol. 2011, 80, 839-847
17. Chen, B. L.; Chen, Y.; Tu, J. H.; Li, Y. L.; Zhang, W.; Li, Q.; Fan, L.; Tan, Z. R.; Hu, D. L.; Wang, D.; Wang, L. S.; Ouyang, D. S.; Zhou, H. H. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms J. Clin. Pharmacol. 2009, 49, 574-581
18. Alla, V. A.; Vyakaranam, K. A.; Sirigiri, A. K.; Bodapati, S. R.; Billa, R. R.; Gudibandi, S. R.; Alla, R. Process for Preparation of Clopidogrel Bisulphate Form-1. US 2007/0191609 A1, 2007.
19. Shan, J.; Zhang, B.; Zhu, Y.; Jiao, B.; Zheng, W.; Qi, X.; Gong, Y.; Yuan, Y.; Lv, F.; Sun, H. Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent J. Med. Chem. 2012, 55, 3342-3352
20. Born, G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 1962, 194, 927-929
21. Kim, J. Y. Strategy for the treatment of clopidogrel low responsiveness in diabetes mellitus and stent implantation Korean Circ. J. 2009, 39, 459-461
22. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs Nat. Rev. Drug Discovery 2011, 10, 307-317